Related Experiment Video

Updated: Aug 19, 2026

Facile Preparation and Photoactivation of Prodrug-Dye Nanoassemblies
08:54

Facile Preparation and Photoactivation of Prodrug-Dye Nanoassemblies

Published on: February 17, 2023

Development of prodrugs for enzyme-mediated, tumor-selective therapy

K Jin Yoon1, Philip M Potter, Mary K Danks

  • 1Department of Molecular Pharmacology, St. Jude Children's Research Hospital, 332 N. Lauderdale, Memphis, TN 38105, USA.

Current Medicinal Chemistry. Anti-Cancer Agents
|March 22, 2005
PubMed

Insights

Enzyme/prodrug cancer therapies aim to activate drugs at tumor sites, minimizing toxicity. This review compares seven combinations and suggests future directions for improved anticancer efficacy.

Area of Science:

  • Oncology
  • Pharmacology
  • Biochemistry

Background:

  • Enzyme/prodrug anticancer strategies are designed for targeted activation at tumor sites.
  • Current approaches show limited success, necessitating exploration of more effective combinations.
  • Minimal toxicity is a key objective for these targeted therapies.

Purpose of the Study:

  • To evaluate and compare the characteristics of seven selected enzyme/prodrug combinations.
  • To identify key features contributing to the efficacy and limitations of existing strategies.
  • To outline future research goals for developing superior enzyme/prodrug therapeutic combinations.

Main Methods:

  • Literature review and comparative analysis of seven distinct enzyme/prodrug systems.
  • Evaluation of prodrug activation mechanisms, enzyme specificities, and tumor targeting efficiencies.
  • Assessment of preclinical and clinical data where available.

Main Results:

  • Variability in tumor specificity and prodrug activation efficiency among the reviewed combinations.
  • Identification of specific enzyme/prodrug pairs with promising antitumor activity and reduced systemic toxicity.
  • Challenges in achieving consistent and robust therapeutic outcomes across different tumor types.

Conclusions:

  • Enzyme/prodrug therapy holds significant potential but requires optimization for clinical success.
  • Future development should focus on enhancing tumor selectivity and prodrug conversion rates.
  • Further research into novel enzyme/prodrug systems and delivery methods is crucial for advancing cancer treatment.

Related Concept Videos

Prodrugs01:30

Prodrugs

Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...